Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini
Ryvu Therapeutics (WSE:RVU) today announced the online publication of two posters and an oral presentation demonstrating clinical…